title: Safety and Efficacy of GreenLight XPS Laser Vapoenucleation in Prostates Measuring Over 150 mL.
abstract: The GreenLight™ XPS Laser System (GL-XPS) is a safe and efficacious treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH), but there is limited evidence on its use in prostates over 150 mL. We demonstrate the safety and efficacy of the GL-XPS system using a vapoenucleation technique in prostate glands measuring over 150 mL.
  
  
  
  We prospectively collected data on all consecutive patients with prostates measuring over 150 mL on transrectal ultrasound treated with the GL-XPS (AMS, Inc., Minnetonka, MN) at a tertiary referral center from September 2011 to October 2015. Data collected include prostate volume, International Prostate Symptom Score (IPSS) and quality of life (QoL) scores, maximum urinary flow rate (Qmax), postvoid residual (PVR), prostate-specific antigen, complications, and reintervention rates.
  
  
  
  Seventy male patients with a median prostate size of 202 mL (range 152-376 mL) were included. There were 41 patients (59%) in preoperative urinary retention with an indwelling catheter preoperatively. Thirty-seven (53%) patients were American Society of Anesthesiologists (ASA) class 2 and 33 (47%) were class 3. Median operative time was 180 minutes, laser time 97 minutes, energy utilization 674 kJ, and energy density 3.3 kJ/mL, with median 3 fibers used per case. Median length of stay and length of catheterization were 1 day. IPSS and QoL scores demonstrated significant improvements from baseline at all endpoints, improving from 16 to 3.5 and from 4 to 1 at 24 months, respectively (p = 0.001). At 12 months, Qmax and PVR improved from 10.1 to 22.4 mL/s (p = 0.043) and from 84 to 31.4 mL (p = 0.015), respectively. Retreatment was required in two patients (2.9%).
  
  
  
  GL-XPS vapoenucleation provided durable subjective and objective improvements in symptoms and voiding parameters, with no serious adverse events in men with prostates >150 mL.
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: Benjamin V
authors.initials: BV
authors.lastname: Stone
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: Bilal
authors.initials: B
authors.lastname: Chughtai
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: James C
authors.initials: JC
authors.lastname: Forde
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Tam
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: Patrick
authors.initials: P
authors.lastname: Lewicki
authors.affiliation: Department of Urology, Weill Cornell Medical College, New York-Presbyterian Hospital , New York, New York.
authors.forename: Alexis E
authors.initials: AE
authors.lastname: Te
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D007902:Length of Stay; D059411:Lower Urinary Tract Symptoms / Q000209:etiology / Q000601:surgery*; D008297:Male; D061646:Operative Time; D009929:Organ Size; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000150:complications / Q000473:pathology / Q000601:surgery*; D011788:Quality of Life; D012449:Safety; D013997:Time Factors; D016896:Treatment Outcome; D014546:Urinary Catheterization; D016055:Urinary Retention / Q000209:etiology / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen